Analisis Keuangan Saham SBLOF - Shin Nippon Biomedical Laboratories, Ltd. (OTCPK) Stock

Shin Nippon Biomedical Laboratories, Ltd.
US ˙ OTCPK ˙ JP3379950003

Gambaran Umum
Shin Nippon Biomedical Laboratories, Ltd., based in Japan, operates primarily in the pharmaceuticals and healthcare industry, focusing extensively on preclinical and clinical drug development services. The company offers a comprehensive portfolio of services, including toxicology studies, pharmacokinetics, and drug metabolism studies crucial for regulatory submissions. Key projects often involve collaborative research and development partnerships aimed at advancing innovative therapeutic products. The company supports global pharmaceutical and biotechnology firms in navigating the complexities of drug development, from discovery through to regulatory approval. Shin Nippon Biomedical Laboratories leverages advanced technology and extensive expertise to enhance the efficacy and safety evaluation of new therapeutics, positioning itself as a critical player in the biomedical research field.
Skor Kualitas, Nilai, dan Momentum

Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.

Kualitas

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Nilai

Model penilaian eksklusif yang memberi peringkat pada perusahaan berdasarkan valuasi relatifnya. Skor berkisar antara 0 hingga 100, dengan 100 sebagai yang paling diremehkan nilainya.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Sentimen Dana

Skor Sentimen Dana (sebelumnya dikenal sebagai Skor Kepemilikan) adalah model kuantitatif eksklusif yang memberi peringkat pada perusahaan berdasarkan tingkat akumulasi kepemilikan.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
  • Nilai revenue untuk Shin Nippon Biomedical Laboratories, Ltd. per 2025 Jun 30 adalah 33,341.96 MM.
  • Nilai operating income untuk Shin Nippon Biomedical Laboratories, Ltd. per 2025 Jun 30 adalah 2,789.48 MM.
  • Nilai net income untuk Shin Nippon Biomedical Laboratories, Ltd. per 2025 Jun 30 adalah 5,063.08 MM.
Period End (TTM) Revenue (MM) Operating Income (MM) Net Income (MM)
2025-06-30 33,341.96 2,789.48 5,063.08
2025-03-31 32,413.00 2,985.00 4,924.00
2024-12-31 30,701.11 3,520.59 4,942.16
2024-09-30 27,074.00 1,892.00 3,896.00
2024-06-30 26,195.02 2,790.09 4,280.14
2024-03-31 26,450.47 4,162.37 5,531.26
2023-12-31 26,703.00 3,997.00 5,503.00
2023-09-30 26,626.00 5,282.00 4,607.00
2023-06-30 26,848.00 5,758.00 5,489.00
2023-03-31 25,090.00 5,245.00 6,060.00
2022-12-31 21,173.00 4,679.00 6,231.00
2022-09-30 20,135.00 4,540.00 8,043.00
2022-06-30 18,753.00 4,418.00 7,245.00
2022-03-31 17,748.00 4,196.00 7,127.00
2021-12-31 17,636.00 4,204.00 7,432.00
2021-09-30 16,068.00 3,337.00 6,025.00
2021-06-30 14,978.00 2,573.00 4,844.00
2021-03-31 15,110.00 2,529.00 3,661.00
2020-12-31 14,910.00 2,278.00 2,421.00
2020-09-30 15,175.00 2,311.00 2,812.00
2020-06-30
2020-03-31
Laporan Laba Rugi: EPS
Period End (TTM) Earnings Per Share Basic Earnings Per Share Diluted
2025-06-30
2025-03-31
2024-12-31 118.71 118.71
2024-09-30 93.58 93.58
2024-06-30 102.81 102.81
2024-03-31 132.86
2023-12-31 132.19 132.19
2023-09-30 110.66 110.66
2023-06-30 131.85 131.85
2023-03-31 145.56
2022-12-31 149.67 149.67
2022-09-30 193.20 193.20
2022-06-30 174.02 174.02
2022-03-31 171.19
2021-12-31 178.52 178.52
2021-09-30 144.72 144.72
2021-06-30 116.35 116.35
2021-03-31 87.94
2020-12-31 58.15 58.15
2020-09-30 67.54 67.54
2020-06-30 77.68 77.68
2020-03-31 61.25
Arus Kas: Operasi, Investasi, Pendanaan
Period End (TTM) Cash From Operating Activities (MM) Cash From Investing Activities (MM) Cash From Financing Activities (MM)
2025-06-30
2025-03-31 7,035.00 -11,691.00 5,914.00
2024-12-31
2024-09-30 1,650.00 -10,758.00 10,852.00
2024-06-30
2024-03-31 2,106.73 -6,907.73 5,318.66
2023-12-31
2023-09-30 1,899.00 -7,022.00 2,120.00
2023-06-30
2023-03-31 4,004.00 -5,930.00 6,266.00
2022-12-31
2022-09-30 7,170.00 -7,227.00 4,280.00
2022-06-30
2022-03-31 5,952.00 -4,268.00 -4,911.00
2021-12-31
2021-09-30 5,301.00 444.00 -4,915.00
2021-06-30
2021-03-31 4,746.00 -268.00 -2,471.00
2020-12-31
2020-09-30 2,706.00 -1,277.00 -613.00
2020-06-30
2020-03-31
Metrik Penilaian: PE, PriceToBook, PriceToTBV
P/Book
The current closing price divided by the book value per share.
P/TBV
The current price divided by the tangible book value per share.
Period End (TTM) p/e P/Book P/TBV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
Period End (TTM) EBIT/EV EBIT (3y)/EV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
Efektivitas Manajemen
  • roa untuk Shin Nippon Biomedical Laboratories, Ltd. pada 2025 Jun 30 adalah 0.06.
  • roe untuk Shin Nippon Biomedical Laboratories, Ltd. pada 2025 Jun 30 adalah 0.15.
  • roic untuk Shin Nippon Biomedical Laboratories, Ltd. pada 2025 Jun 30 adalah 0.07.
  • croic untuk Shin Nippon Biomedical Laboratories, Ltd. pada 2025 Jun 30 adalah 0.02.
  • ocroic untuk Shin Nippon Biomedical Laboratories, Ltd. pada 2025 Jun 30 adalah 0.10.
Period End (TTM) ROA ROE ROIC (Tingkat Pengembalian Investasi Modal) CROIC OCROIC
2025-06-30 0.06 0.15 0.07 0.02 0.10
2025-03-31 0.06 0.14 0.06 0.02 0.02
2024-12-31 0.05 0.13 0.05 0.03 0.02
2024-09-30 0.06 0.13 0.06 0.02 0.03
2024-06-30 0.21
2024-03-31 0.19
2023-12-31 0.14 -0.08
2023-09-30 0.20 0.17
2023-06-30 0.26
2023-03-31 0.31
2022-12-31
2022-09-30 0.00
2022-06-30 0.00 0.00
2022-03-31 0.00
2021-12-31 0.00
2021-09-30 0.17 0.41
2021-06-30 0.12 0.16 0.07 0.16
2021-03-31 0.09 0.22 0.13 0.07 0.17
2020-12-31 0.06 0.14 0.08 0.03 0.09
2020-09-30 0.06 0.13 0.10 0.03 0.09
2020-06-30 0.07 0.13 0.09 0.00 0.09
2020-03-31 0.05 0.09 0.08 0.00 0.10
Gross Margins
  • marjin kotor untuk Shin Nippon Biomedical Laboratories, Ltd. pada 2025 Jun 30 adalah 0.45.
  • marjin bersih untuk Shin Nippon Biomedical Laboratories, Ltd. pada 2025 Jun 30 adalah 0.15.
  • marjin operasi untuk Shin Nippon Biomedical Laboratories, Ltd. pada 2025 Jun 30 adalah 0.09.
Margin Kotor
The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
Margin Keuntungan Bersih
Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
Margin Operasi
Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) Margin Kotor Margin Keuntungan Bersih Margin Operasi
2025-06-30 0.45 0.15 0.09
2025-03-31 0.49 0.16 0.11
2024-12-31 0.48 0.14 0.07
2024-09-30 0.49 0.16 0.11
2024-06-30
2024-03-31
2023-12-31
2023-09-30 0.20 0.21
2023-06-30 0.20 0.21
2023-03-31 0.24 0.21
2022-12-31
2022-09-30 0.00 0.00
2022-06-30 0.00 0.00
2022-03-31
2021-12-31
2021-09-30
2021-06-30 0.50 0.32 0.17
2021-03-31 0.46 0.24 0.17
2020-12-31 0.50 0.16 0.15
2020-09-30 0.50 0.19 0.15
2020-06-30 0.51 0.22 0.16
2020-03-31 0.52 0.18 0.15
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK)
Grupong Pang-industriya
Other Listings
JP:2395 JP¥ 1,695.00
DE:YB3 € 9.75
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista